Table 2.

List of In-111- and Y-90-labeled monoclonal antibodies.

Compound	Description	Applications	Remarks
In111-Capromab pendetide (ProstaScint)	A conjugation between the murine antibody 7E11.C5.3 and 111In  in the source of 111InCl3 by the action of the GYK-DTPA as a chelating agent.	Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis.	It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma.
In111-Satumomab pendetide (OncoScint)	It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with 111InCl3 by conjugation with the chelating agent, GYK-DTPA.HCl.	Used for the detection of colorectal and ovarian cancers [35].	After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours.
In111-Imciromab pentetate (MyoScint)	An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration.	Detection of myocardial infarction.	Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving 111In -Imciromab pentetate.
In-111 and Y90-ibritumomab tiuxetan (Zevalin)	Zevalin consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with 111In  for imaging and with 90Y for therapy.	90Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its 111In  derivative is used to scan the predicted distribution of a therapeutic dosage of 90Y-ibritumomab in the body [36].	The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37].
Rituximab	An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL).	It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL.	In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy.